WSD0694

WSD0694 is an investigational small molecule drug being developed by Wayshine Biopharm. It is part of the company's pipeline of innovative anti-cancer therapies, which primarily focuses on central nervous system (CNS) penetrable agents for the treatment of various malignancies, including brain cancers such as glioma. While specific details regarding its biological target and mechanism of action have not been extensively disclosed in public clinical registries or publications, it is positioned within a portfolio that emphasizes DNA damage response (DDR) inhibitors and kinase inhibitors designed to cross the blood-brain barrier. The drug is currently in the discovery or preclinical stage of development.